Becton, Dickinson and Co
(XSWX:BDX)
CHF
243.41
0 (0%)
Market Cap: 63.44 Bil
Enterprise Value: 78.37 Bil
PE Ratio: 37.37
PB Ratio: 2.48
GF Score: 85/100 Becton Dickinson and Co at Wells Fargo Healthcare Conference Transcript
Sep 06, 2023 / 12:45PM GMT
Lawrence H. Biegelsen
Wells Fargo Securities, LLC, Research Division - Senior Medical Device Equity Research Analyst
Good morning. I'm Larry Biegelsen, the medical device analyst at Wells Fargo. It's my pleasure to host this fireside chat with the management team from BD. With us, we have Tom Polen, Chairman, President and CEO and Chris DelOrefice, Executive Vice President and CFO.
In terms of format, as I said, it's going to be a fireside chat. If anybody has a question they want to ask, just raise your hand. And so with that, we'll jump in.
Tom and Chris, thanks so much for being here.
Thomas E. Polen
Becton, Dickinson and Company - President, CEO & Chairman
Great to be here.
Lawrence H. Biegelsen
Wells Fargo Securities, LLC, Research Division - Senior Medical Device Equity Research Analyst
So Tom, let's start with Alaris, which was cleared recently by FDA. It was obviously a very important milestone for the company. I think you said in the past it was your #1 priority. So
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot